Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03459859 · ClinicalTrials.gov registry record · Phase 1
Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS
A Phase 1 study, sponsored by Justin Watts, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03459859 is a Phase 1 study that has completed, run by Justin Watts, MD. The registered enrollment target is 12 participants.
The verdict
NCT03459859, a Phase 1 study, has completed, sponsored by Justin Watts, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The investigators hypothesize that the combination of Pevonedistat/Low-Dose Cytarabine (LDAC) therapy will be tolerable, that a recommended phase 2 dose of Pevonedistat in combination with LDAC will be identified, and that the combination therapy will show evidence of clinical activity in adult patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML) and Advanced Myelodysplastic Syndromes (MDS).
Interventions
- DRUG Cytarabine
- DRUG Pevonedistat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-05-21 |
| Est. Completion | 2021-06-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03459859
The ClinicalTrials.gov registry entry for NCT03459859 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Justin Watts, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cytarabine is the first listed.
NCT03459859 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03459859 about?
NCT03459859 is a clinical study titled "Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS". The investigators hypothesize that the combination of Pevonedistat/Low-Dose Cytarabine (LDAC) therapy will be tolerable, that a recommended phase 2 dose of Pevonedistat in combination with LDAC will be identified, and that the combination therapy will show evidence of clinical activity in adult pati...
What is the current status of trial NCT03459859?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2018-05-21. Estimated completion is 2021-06-25.
What interventions are being tested in trial NCT03459859?
The interventions under investigation include: Cytarabine (DRUG), Pevonedistat (DRUG).
Who is sponsoring clinical trial NCT03459859?
This trial is sponsored by Justin Watts, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.